UCB, which has entered into an agreement granting it worldwide exclusive rights to develop, manufacture, and commercialize ATG-201,, is now advancing that mechanism through its agreement with Antengene covering ATG-201,, a separate CD19×CD3 bispecific T-cell engager, which just dosed its first patient in the Phase I ATTRACT study in China. That a major pharmaceutical company has moved to secure global rights to a CD19xCD3 program tells you something about how competitive this space has become: across oncology and immunology, a growing number of CD3-targeting bispecific T-cell engagers have received FDA or EMA approval in recent years,, and the race to extend the mechanism into autoimmune indications is well underway.
ATTRACT is a two-part Phase I trial enrolling adult patients with B cell-mediated autoimmune diseases, opening first in China under principal investigator Prof. Zhanguo Li of Peking University People’s Hospital. Part one is dose escalation; part two is dose expansion. The primary endpoints are safety, tolerability, and identifying the recommended Phase II dose. The trial is also cleared to open in Australia, where ATG-201 has received ethics committee approval and completed the Clinical Trial Notification process with the Therapeutic Goods Administration. Antengene retains responsibility for running both country arms while UCB holds commercialization rights globally.
What distinguishes ATG-201 on paper is its steric hindrance masking technology, built into Antengene’s AnTenGager platform. The design is meant to minimize cytokine release syndrome while preserving potent action against CD19-expressing B cells,, with the goal of reducing cytokine release syndrome while preserving potency against CD19-expressing B cells. Whether that translates into a cleaner clinical profile than competing agents is exactly what ATTRACT is designed to test. Patients with refractory B cell-mediated autoimmune diseases often cycle through steroids and off-label B-cell depletion with limited durable benefit, so the bar for efficacy data that could differentiate a new mechanism is real, not just theoretical.
The most concrete near-term signal to track from ATTRACT is the Part I dose-escalation safety readout, specifically the cytokine release syndrome rate and severity at each dose level. That data will determine whether the masking technology performs as designed and set the ceiling for how aggressively the program can move into expansion cohorts.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
